Relay Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 323
- Market Cap
- $955.9M
- Website
- http://www.relaytx.com
- Introduction
Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery....
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Relay Therapeutics, Inc.
- Target Recruit Count
- 265
- Registration Number
- NCT05759949
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Community Cancer Center North, Indianapolis, Indiana, United States
🇺🇸Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Relay Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05216432
- Locations
- 🇺🇸
University of California-San Diego, San Diego, California, United States
🇺🇸Washington University School of Medicine St. Louis, Saint Louis, Missouri, United States
🇺🇸Rutgers University, New Brunswick, New Jersey, United States
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-08-25
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Relay Therapeutics, Inc.
- Target Recruit Count
- 540
- Registration Number
- NCT04526106
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸The University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States